Search

Displaying results 4701 - 4710 of 7540 in total
  1. Drug

    ADX-10061

    go.drugbank.com/drugs/DB05419
    Experimental

    It is developed by Addex Pharmaceuticals for the treatment of nicotine dependence.

  2. Drug

    Oxyphenonium

    go.drugbank.com/drugs/DB00219
    Approved

    A quaternary ammonium anticholinergic agent with peripheral side effects similar to those of atropine. … It is used as an adjunct in the treatment of gastric and duodenal ulcer, and to relieve visceral spasms. The drug has also been used in the form of eye drops for mydriatic effect. [PubChem]

  3. Drug

    Otelixizumab

    go.drugbank.com/drugs/DB05496
    Investigational

    Otelixizumab is a monoclonal antibody that binds to a receptor found on all T cells called CD3, which is involved in normal T cell signaling. … Tolerx is developing otelixizumab to treat patients with type 1 diabetes, psoriasis and other autoimmune diseases such as rheumatoid arthritis.

  4. Drug

    Iodipamide

    go.drugbank.com/drugs/DB04711
    ApprovedWithdrawn

    Iodipamide is a water-soluble radiographic contrast media for cholecystography and intravenous cholangiography.

  5. Drug

    Prenylamine

    go.drugbank.com/drugs/DB04825
    ApprovedWithdrawn

    Prenylamine was withdrawn from the Canadian, US, and UK markets in 1988 due to concerns regarding cardiac arrhythmias.

    Synonyms: N-(3,3-Diphenylpropyl)-alpha-methylphenaethylamin, N-(3,3-Diphenylpropyl)-alpha-methylphenethylamine
  6. Drug

    BI 4060107

    go.drugbank.com/drugs/DB33963
    Experimental

    BI 4060107 is under investigation in clinical trial NCT07827144 (A Study to Test How Well Different Doses of BI 4060107 Are Tolerated by People With Advanced Cancer (Solid Tumours)).

  7. Drug

    Allogenic Donor CD362-enriched Human Umbilical Cord-derived Mesenchymal Stem Cells

    go.drugbank.com/drugs/DB15731
    Investigational

    be hypoimmunogenic and non-inducible for tumorigenesis. … The isolated cells are expanded in culture and are able to be used allogenically -- meaning that one donor’s cells can be given to other unrelated patients.

  8. Drug

    SO-101

    go.drugbank.com/drugs/DB05345
    Experimental

    SO-101(Silenor) is a low-dose oral tablet formulation of doxepin hydrochloride that is patent protected for its use in insomnia. … Doxepin has been prescribed for more than 40 years for the treatment of depression and anxiety at dosages typically ranging from 75 mg to 300 mg per day.

  9. Drug

    Ulevostinag

    go.drugbank.com/drugs/DB14721
    Investigational

    Specifically, expression of IFN-beta (IFNb) enhances the cross-presentation of tumor-associated antigens by CD8alpha-positive and CD103-positive dendritic cells (DCs) to cytotoxic T lymphocytes (CTLs). … factor-kappa B (NF-kB) and interferon regulatory factor 3 (IRF3) in immune cells in the tumor microenvironment; this leads to the production of pro-inflammatory cytokines, including interferons (IFNs)

    Synonyms: Guanosine, (p(r))-2'-deoxy-2'-fluoro-5'-o-((r)-hydroxymercaptophosphinyl)-p-thio-.beta.-d-arabino-adenylyl-(3'->5')-3'-deoxy-3'-fluoro-, cyclic nucleotide
  10. Drug

    SYNB1353

    go.drugbank.com/drugs/DB17666
    Investigational

    [A258833] Developed by Synlogic Operating Company, Inc., SYNB1353 is being investigated for the treatment of homocystinuria. … It is designed to consume methionine in the gastrointestinal tract to prevent its absorption and conversion into homocysteine.[L45983]